

23 November 2009

IS Pharma plc ('IS Pharma')

Variquel® (Haemopressin®) Update

IS Pharma plc (LSE: ISPH), the international speciality pharmaceutical company, is pleased to announce that marketing authorisations (MAs) for Variquel have now been received for all of the major European markets, specifically the UK, France, Spain and Italy. Furthermore, MAs have also been received for Belgium, Denmark, Finland, Ireland, Luxembourg, Netherlands, Portugal and Sweden.

IS Pharma acquired Variquel in April 2008 when it was marketed only in Germany, Austria and Switzerland. Since then we have successfully completed the European Mutual Recognition Procedure and subsequently obtained the abovementioned MAs, which has enabled IS Pharma to launch Variquel in the UK, France, Ireland, Denmark, Netherlands, Portugal, Sweden and Finland. Launches in the other European markets are expected shortly.

Variquel is a key brand for IS Pharma in a global market that is estimated at between £50 million - £70 million. Variquel is a rapid-acting vasoconstrictor used in the treatment of oesophageal varices.

Tim Wright, CEO of IS Pharma, said:

"We are very pleased to announce this significant milestone for IS Pharma. The launches of Variquel across Europe further emphasises the growing internationalisation of our business. Our success in acquiring Variquel, achieving European MRP and subsequent national approvals, once again clearly demonstrates our ability to progress products through complex regulatory processes and onto commercialisation."

-Ends-

For further information, call:

IS Pharma plc

Tel: +44(0) 1244 625150

Tim Wright – CEO / Matthew Hall - CFO

Financial Dynamics Limited

Tel: +44(0) 20 7831 3113

Billy Clegg / Edward Westropp

Piper Jaffray Ltd

Tel: +44 (0) 20 3142 8700

Neil Mackison / Rupert Winckler

About IS Pharma plc (AIM: ISPH)

IS Pharma (International Speciality Pharmaceuticals) is a fast growing, profitable business which develops, acquires and commercialises late-stage pharmaceuticals and medical devices, focusing in critical care, oncology and neurology. Based in the UK, IS Pharma commercialises its portfolio in the UK directly and internationally through a strong network of distributors.

To find out more please go to [www.ispharma.plc.uk](http://www.ispharma.plc.uk)